<VariationArchive VariationID="1458129" VariationName="NC_000011.9:g.(?_111959581)_(111965694_?)del" VariationType="Deletion" Accession="VCV001458129" Version="6" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2022-03-28" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1471693" VariationID="1458129">
      <GeneList>
        <Gene Symbol="SDHD" FullName="succinate dehydrogenase complex subunit D" GeneID="6392" HGNC_ID="HGNC:10683" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>11q23.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112086873" stop="112095794" display_start="112086873" display_stop="112095794" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="111957570" stop="111966517" display_start="111957570" display_stop="111966517" Strand="+" />
          </Location>
          <OMIM>602690</OMIM>
          <Haploinsufficiency last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000011.9:g.(?_111959581)_(111965694_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q23.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="111959581" innerStop="111965694" display_start="111959581" display_stop="111965694" variantLength="6114" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_111959581)_(111965694_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_111959581)_(111965694_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.9:g.(?_111959581)_(111965694_?)del AND multiple conditions" Accession="RCV001972806" Version="6">
        <ClassifiedConditionList TraitSetID="73586">
          <ClassifiedCondition DB="MedGen" ID="C1847319">Carney-Stratakis syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN166604">Cowden syndrome 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1868633">Paragangliomas with sensorineural hearing loss</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-08-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2023-11-11">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11897817</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19454582</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20111059</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22382802</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25720320</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="73586" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3265" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carney-Stratakis syndrome</ElementValue>
                <XRef ID="MONDO:0011740" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastrointestinal stromal tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and GIST</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney-Stratakis dyad of paraganglioma and gastric stromal sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney dyad</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastric stromal sarcoma</ElementValue>
                <XRef ID="Paraganglioma+and+gastric+stromal+sarcoma/5577" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10643" />
                <XRef ID="10643" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="97286" DB="Orphanet" />
              <XRef ID="C1847319" DB="MedGen" />
              <XRef ID="MONDO:0011740" DB="MONDO" />
              <XRef Type="MIM" ID="606864" DB="OMIM" />
            </Trait>
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="17663" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cowden syndrome 3</ElementValue>
                <XRef ID="MONDO:0014045" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CWS3</ElementValue>
              </Symbol>
              <XRef ID="201" DB="Orphanet" />
              <XRef ID="CN166604" DB="MedGen" />
              <XRef ID="MONDO:0014045" DB="MONDO" />
            </Trait>
            <Trait ID="8850" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas with sensorineural hearing loss</ElementValue>
              </Name>
              <XRef ID="C1868633" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4257253" SubmissionDate="2023-02-03" DateLastUpdated="2023-11-11" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_003002.3_Deletion (Exons 3-4)|MedGen:C1847319;C1868633;C0031511;C3554516" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002239500" DateUpdated="2023-11-11" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11897817</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19454582</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20111059</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22382802</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25720320</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11897817</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19454582</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20111059</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22382802</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25720320</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 3-4 of the SDHD gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. A similar copy number variant has been observed in individual(s) with paragangliomas and have been determined to be pathogenic (PMID: 11897817, 19454582, 20111059, 22382802, 25720320; Invitae). The region of the SDHD gene that includes exon(s) 4 has been determined to be clinically significant (PMID: 11897817, 19454582, 20111059, 22382802, 25720320; Invitae). Therefore, deletions that encompass that region are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_111959581)_(111965694_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1847319" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1868633" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0031511" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3554516" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4257253" TraitType="Disease" MappingType="XRef" MappingValue="C0031511" MappingRef="MedGen">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4257253" TraitType="Disease" MappingType="XRef" MappingValue="C3554516" MappingRef="MedGen">
        <MedGen CUI="CN166604" Name="Cowden syndrome 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4257253" TraitType="Disease" MappingType="XRef" MappingValue="C1847319" MappingRef="MedGen">
        <MedGen CUI="C1847319" Name="Carney-Stratakis syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4257253" TraitType="Disease" MappingType="XRef" MappingValue="C1868633" MappingRef="MedGen">
        <MedGen CUI="C1868633" Name="Paragangliomas with sensorineural hearing loss" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

